Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05471_nanopub.RAByqythBwDp0i5_mRvlSqq9XpRiznQKrq5SfIJat7XwI#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05471 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05471 label "SGN-30 [drugbank:DB05471]" assertion.
- drugbank:DB05471 seeAlso DB05471 assertion.
- drugbank:DB05471 description "SGN-30 is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy. SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. We are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric ALCL. SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas." assertion.
- drugbank:DB05471 identifier "drugbank:DB05471" assertion.
- drugbank:DB05471 title "SGN-30" assertion.
- drugbank:DB05471 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05471 drugbank_vocabulary:drugbank-id "DB05471" assertion.
- drugbank:DB05471 bio2rdf_vocabulary:x-identifiers.org DB05471 assertion.
- drugbank:DB05471 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05471" assertion.
- drugbank:DB05471 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05471 bio2rdf_vocabulary:identifier "DB05471" assertion.